Member Info for Lazarus2

I think we may tick up again Aber with the bid at 2.24 we will see 2.3 soon on the ask

This is overdue by about 2 days - The bid is only just reflecting what was being paid yesterday and the day before.
Definitely been suppressed, but thats the nature of the beast.
All good here and news is getting ever closer.

MXV - Italian for this is Innuendo

If you only deal with facts Bluenose, why are you speculating on the stock market

late trade showing up from 1538hrs at 2.35p. 18k of them. there has been some chunky buying of late around this level. I wonder if we have an iceberg trade in place.

It*

PH fall into this bracket and some of you may be interested. I may shed some light on why they have been appointed

https://irsociety.org.uk/files/_corporate_broker.pdf

Chillax guys - still 13.5m shares traded on a Friday and a rising sp.

Same trading pattern as yesterday - sp stuck at this level while orders filled, with larger orders at 2.33 being filled and put through. PH and Co know what is coming and when giving them the room to mess with the sp where necessary.
Just soak up the frustration and wait for the reward. Out lasting the mms/brokers is one of the few ways to win.

Thanks for the clarification Bill. Somebody else has a lot of confidence in Sareum also.

I would not disagree with your (RMM) synopsis. We are definitely on the cusp.

Looks like Billy may have thrown his £70k in along with a few others.

How long is a piece of string Bill. Difficult question to answer as it will very much depend on GSK approach to taking SRA737 on board. There is also other positive news due.
The second part of my response is down to anticipated market cap that any news or progress would add to the value. With only 68m shares in circulation the sp could go quite high. I am not going to predict anything as it is a bit of a mugs game.
The final factor is your own approach to risk. If you are looking for a short term win then set your targets low. If you have time on your side and the news is good then you should make a healthy profit on any purchases £3 or below.
Hope this helps

Somebody bought 20k shares @ £2.33 - showing as a delayed trade. That’s not a just for fun trade.

Hi Desamax,

Dilly presented at Oppenheimer Healthcare March 15th. Krone has been good at posting these items. Dilly also presented April. Clearly, he was under NDA constraints right throughout the negotiations and explains the lack of information relating to SRA737.

Sierra doing exactly the correct thing by their employees and shareholders. They remain a stand alone company at this moment in time and so should act as such. There shouldn't be any impediment to the deal with GSK going through but you never know. They would have egg on their face if it fell through and they had lost 6 months development as a result of complacency.
As for staff recruitment. Great opportunity to potentially work within the GSK framework going forwards and all of the opportunities that will undoubtedly exist.
Sareum will also have its day in the sunshine.

I suspect there are several orders at these levels waiting for sellers baling out in order to be able to fill them. Bit of an uphill task for the MMs at the moment - not many big sellers around at all. Volume choked and very little movement

Sareum have a ready made and developing R&D profile

Fascinating period in Sareums development Basser. I am not sure that there would be too much short term influence over our direction of travel. I must admit I had first thought that AZN were positioning themselves after their flirtation with Sierra. Gilead could also be in the mix.
The obvious one emerging from the pack is GSK after their purchase of Sierra who license SRA737. Given the BoD's past association with GSK and the fact that GSK are stated to be looking to float off their R&D arm, it would appear that ducks are aligning.
I could be wrong though and have no specific knowledge. Highest bidder would win, but the Industry appears to me to be quite incestuous - my money is on a collaboration with GSK.

Looking at our market cap from here we are currently valued at circa £153m taking a sp of £2.25. In the past we have all been reasonably pragmatic regarding valuations given Sareum were "work in progress". We are now in a much stronger position then ever before with SRA737, Covid/respiratory diseases, 1801 and 1802 developments now about to bear fruit. Coupled with our patents I feel that Sareum is now undervalued. The market is risk averse at the moment but with Tox reports for 1801 showing clear (and likely to be matched by 1802) there has never been a better opportunity to invest cheaply.
The news pipeline is looking very healthy IMO with the potential for significant rises in a short period of time. I am not going into forecasting the sp but I do think we will see new highs for the sp very soon. With only 68m shares in circulation demand will very rapidly outstrip supply. A perfect storm is approaching

You ok Warty?